Erectile dysfunction (ED) is a common problem with a multifactorial aetiolo
gy. The treatment of ED has been revolutionised by the introduction of intr
acavernosal injections some two decades ago. However, the recent developmen
t of the orally-administered drug sildenafil (Viagra (TM)) was had a major
impact on the treatment of ED. We discuss the trials with sildenafil with s
pecial reference to cardiovascular risk factors associated with ED.